Equity Profile

DNLI

Denali Therapeutics Inc.

Health CareBiotechnology$4.0B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

Research and Development Expenses

This metric indicates how much the company is investing in developing new therapies, which is crucial for its growth prospects.

N/A

Clinical Trial Progress

Updates on clinical trials can significantly impact investor sentiment and stock performance, especially if results are positive.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. With a market cap of $4 billion, it operates in the health care sector, addressing significant medical needs in areas like Alzheimer's and Parkinson's diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1 2026, Denali reported an EPS of -$0.69, beating estimates by 5.48%. However, the stock fell 3.43% the next day, reflecting investor caution.

Management Promises & Guidance

Focus on advancing clinical trials for neurodegenerative therapies.
Maintain transparency regarding research and development progress.
Commit to managing operational costs effectively.

Expectations

Wall Street Expectations

Investors are watching closely as Denali prepares to report its Q2 2026 earnings, especially given its recent performance and the lack of analyst estimates.

Bull Case

If Denali shows significant progress in its clinical trials and manages to reduce its cash burn, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to provide clear updates on its clinical trials or reports a higher cash burn than expected, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials for its neurodegenerative therapies?

Investors will closely monitor trial results as they are critical for the company's future growth and market perception.

How is Denali managing its cash burn rate in light of ongoing research and development?

Understanding the cash burn rate will help investors gauge the company's financial health and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Denali's potential for clinical trial success, given its strong historical performance in trial outcomes.

Supporting Evidence

Denali has consistently beaten EPS estimates in the past, indicating potential for positive surprises.

The options market is pricing in a significant move, suggesting that investors are anticipating volatility based on trial updates.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on balancing investment in R&D while managing operational costs effectively.

Bull Confirmed If

Demonstrating a significant reduction in cash burn, ideally below $30 million per quarter, would confirm the bull case.

Bear Confirmed If

A cash burn exceeding $50 million without clear progress in trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +2.8% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations and raises guidance, history suggests the stock could see an average one-day move of around -2.77%.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react neutrally, reflecting uncertainty.

Miss

If Denali misses expectations, history suggests a potential average one-day decline of -2.88%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials.
2Details on cash management strategies and burn rate.
3Any partnerships or collaborations that may impact R&D.
4Insights into the competitive landscape for neurodegenerative therapies.
5Management's outlook on future revenue streams.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases....

Key Metrics to Watch

Research and Development Expenses

This metric indicates how much the company is investing in developing new therapies, which is crucial for its growth prospects.

N/A

Clinical Trial Progress

Updates on clinical trials can significantly impact investor sentiment and stock performance, especially if results are positive.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

DNLI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+4.03%

Avg Stock Reaction

-2.80%

Last Quarter Recap

In Q1 2026, Denali reported an EPS of -$0.69, beating estimates by 5.48%. However, the stock fell 3.43% the next day, reflecting investor caution.

Management Promises & Guidance

Focus on advancing clinical trials for neurodegenerative therapies.
Maintain transparency regarding research and development progress.
Commit to managing operational costs effectively.

Expectations

Wall Street Expectations

Investors are watching closely as Denali prepares to report its Q2 2026 earnings, especially given its recent performance and the lack of analyst estimates.

Bull Case

If Denali shows significant progress in its clinical trials and manages to reduce its cash burn, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company fails to provide clear updates on its clinical trials or reports a higher cash burn than expected, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials for its neurodegenerative therapies?

Investors will closely monitor trial results as they are critical for the company's future growth and market perception.

How is Denali managing its cash burn rate in light of ongoing research and development?

Understanding the cash burn rate will help investors gauge the company's financial health and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Denali's potential for clinical trial success, given its strong historical performance in trial outcomes.

Supporting Evidence

Denali has consistently beaten EPS estimates in the past, indicating potential for positive surprises.

The options market is pricing in a significant move, suggesting that investors are anticipating volatility based on trial updates.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on balancing investment in R&D while managing operational costs effectively.

Bull Confirmed If

Demonstrating a significant reduction in cash burn, ideally below $30 million per quarter, would confirm the bull case.

Bear Confirmed If

A cash burn exceeding $50 million without clear progress in trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±27.57%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±27.6% while DNLI has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

48.7%

Calls (45K)P/C Ratio: 3.33Puts (58K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Denali beats expectations and raises guidance, history suggests the stock could see an average one-day move of around -2.77%.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react neutrally, reflecting uncertainty.

Miss

If Denali misses expectations, history suggests a potential average one-day decline of -2.88%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials.
2Details on cash management strategies and burn rate.
3Any partnerships or collaborations that may impact R&D.
4Insights into the competitive landscape for neurodegenerative therapies.
5Management's outlook on future revenue streams.